Search

Your search keyword '"Limpias, Catalina"' showing total 5 results
Start Over Author "Limpias, Catalina"
5 results on '"Limpias, Catalina"'

1. Supplemental Material - Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country

Author

Cifuentes, Claudia, Lombana, Milton, Vargas, Henry, Laguado, Paola, Ruiz-Patiño, Alejandro, Rojas, Leonardo, Navarro, Uriel, Vargas, Carlos, Ricaurte, Luisa, Arrieta, Oscar, Zatarain-Barron, Lucia, Zapata, Leandro, González, Guido, Ortiz, Carlos, Bernal, Laura, Restrepo, Juan G., Viola, Lucia, Grosso, Fabio, Zapata, Ricardo, Mantilla, William, Carranza, Hernán, Bustillo, Iván, Llinas, Néstor, Duarte, Ricardo, Rodríguez, July, Archila, Pilar, Ávila, Jenny, Bermúdez, Maritza, Gámez, Tatiana, Sotelo, Carolina, Otero, Jorge, Forero, Elkin, Lema, Mauricio, Limpias, Catalina, Ordóñez-Reyes, Camila, Mejía, Sergio, Rolfo, Christian, Rosell, Rafael, and Cardona, Andrés F.

Subjects
FOS: Clinical medicine, 111299 Oncology and Carcinogenesis not elsewhere classified
Abstract

Supplemental Material for Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country by Claudia Cifuentes, Milton Lombana, Henry Vargas, Paola Laguado, Alejandro Ruiz-Patiño, Leonardo Rojas, Uriel Navarro, Carlos Vargas, Luisa Ricaurte, Oscar Arrieta, Lucia Zatarain-Barron, Leandro Zapata, Guido González, Carlos Ortiz, Laura Bernal, Juan G. Restrepo, Lucia Viola, Fabio Grosso, Ricardo Zapata, William Mantilla, Hernán Carranza, Iván Bustillo, Néstor Llinas, Ricardo Duarte, July Rodríguez, Pilar Archila, Jenny Ávila, Maritza Bermúdez, Tatiana Gámez, Carolina Sotelo, Jorge Otero, Elkin Forero, Mauricio Lema, Catalina Limpias, Camila Ordóñez-Reyes, Sergio Mejía, Christian Rolfo, Rafael Rosell, Andrés F. Cardona; ONCOL Group and CLICaP in Cancer Control.

Published
2023
Full Text
View/download PDF

2. DETECCIÓN DEL ANTÍGENO Tn EN TUMORES EPITELIALES CON LA LECTINA DE Vicia villosa isolectina B4

Author

Limpias, Catalina, Pérez, Gerardo, Acosta, Jinneth, Vega, Nohora, and Ricaurte, Orlando

Subjects
cuello utero, lectinas, cervix uteri, antigens, uterine cervical neoplasms, neoplasias del cuello uterino, antígenos, células epiteliales, lectins, epithelial cells
Abstract

Antecedentes Los epítopes T, Tn y sTn, se expresan en un alto porcentaje de tumores epiteliales y pueden detectarse con anticuerpos monoclonales y lectinas. Objetivo. Evaluar diferencias de expresión del antígeno Tn en cortes histológicos de epitelios no neoplásicos y tumores epiteliales mediante isolectina B4 de Vicia villosa. Material y métodos. Se evaluaron semicuantitativamente localización, intensidad y porcentaje de expresión del antígeno en carcinomas in-situ e infiltrantes y epitelios no neoplásicos de cérvix, seno y urotelio, mediante isolectina B4. Resultados La expresión de Tn en cérvix predominó en membrana de células no neoplásicas y citoplasma de células tumorales; su intensidad fue mayor en carcinomas in-situ e infiltrantes comparado con epitelio no neoplásico aunque en este el porcentaje de expresión fue mayor. En seno, la expresión de Tn fue predominantemente citoplasmática con intensidad similar, el porcentaje de expresión fué mayor en carcinomas ductales in-situ e infiltrantes. En urotelio no neoplásico y tumoral la expresión de Tn predominó en citoplasma; la intensidad y el porcentaje de expresión fueron mayores en neoplasias no invasivas de bajo y alto grado, mientras que en urotelio no neoplásico fue baja y no hubo tendencia definida en tumores infiltrantes. Conclusiones. La detección del antígeno Tn mediante la lectina VVB4 mostró una mayor extensión de marcación en carcinomas ductales de seno en relación con el epitelio no neoplásico, pero no mostró una tendencia definida entre el tejido normal, ni diferentes etapas del desarrollo de los tumores de cérvix y urotelio. Estos hallazgos pueden atribuirse a la heterogeneidad de los procesos carcinogénicos o a que la especificidad de la lectina VVB4 no está restringida a este antígeno. Background. T, Tn and sTn epitopes are expressed in a large percentage of epithelial tumours and may be detected with monoclonal antibodies and lectins. Objective. Assess differences in expression of Tn antigen in histological sections of non- neoplastic epithelia and epithelial tumors by isolectin B4 from Vicia villosa Materials and methods. The localisation, intensity and percentage of antigen expression in in-situ and infiltrant carcinomas and non-neoplasic epithelial cells from the cervix, breast and urothelium were semi-quantitatively evaluated by B4 isolectin. Results. Tn expression in the cervix predominated in the membrane of non-neoplasic cells and the cytoplasm of tumour cells; its intensity was greater in in-situ and infiltrant carcinomas compared to non-neoplasic epithelial cells, even though such percentage of expression was greater. Tn expression in the breast was predominantly cytoplasmic (having similar intensity). The percentage of expression was greater in in-situ ductal carcinomas and infiltrates. Tn expression in non-neoplasic and tumoural urothelium predominated in the cytoplasm; the intensity and percentage of expression were greater in low and high degree non-invasive neoplasias, whilst this was low in non-neoplasic urothelium and there was no defined tendency in infiltrant tumours. Conclusions. Tn antigen detection by lectin VVB4 showed greater expression in breast ductal carcinomas in relation to non-neoplastic epithelium, but showed on definite trend between the normal tissue and different stages of development of cervical tumors and urothelium. These findings can be related to heterogeneity of the carcinogenic processes or may be attributed to the specificity of the lectin VVB4 is not restricted to Tn antigen

Published
2010

3. Using Vicia villosa lectin (B4 isolectin) for detecting Tn antigen in epithelial tumours

Author

Limpias, Catalina, Pérez, Gerardo, Acosta, Jineth, Vega, Nohora, Ricaurte, Orlando, Limpias, Catalina, Pérez, Gerardo, Acosta, Jineth, Vega, Nohora, and Ricaurte, Orlando

Abstract

Background. T, Tn and sTn epitopes are expressed in a large percentage of epithelial tumours and may be detected with monoclonal antibodies and lectins.Objective. Assess differences in expression of Tn antigen in histological sections of non- neoplastic epithelia and epithelial tumors by isolectin B4 from Vicia villosaMaterials and methods. The localisation, intensity and percentage of antigen expression in in-situ and infiltrant carcinomas and non-neoplasic epithelial cells from the cervix, breast and urothelium were semi-quantitatively evaluated by B4 isolectin.Results. Tn expression in the cervix predominated in the membrane of non-neoplasic cells and the cytoplasm of tumour cells; its intensity was greater in in-situ and infiltrant carcinomas compared to non-neoplasic epithelial cells, even though such percentage of expression was greater. Tn expression in the breast was predominantly cytoplasmic (having similar intensity). The percentage of expression was greater in in-situ ductal carcinomas and infiltrates. Tn expression in non-neoplasic and tumoural urothelium predominated in the cytoplasm; the intensity and percentage of expression were greater in low and high degree non-invasive neoplasias, whilst this was low in non-neoplasic urothelium and there was no defined tendency in infiltrant tumours.Conclusions. Tn antigen detection by lectin VVB4 showed greater expression in breast ductal carcinomas in relation to non-neoplastic epithelium, but showed on definite trend between the normal tissue and different stages of development of cervical tumors and urothelium. These findings can be related to heterogeneity of the carcinogenic processes or may be attributed to the specificity of the lectin VVB4 is not restricted to Tn antigen., Antecedentes Los epítopes T, Tn y sTn, se expresan en un alto porcentaje de tumores epiteliales y pueden detectarse con anticuerpos monoclonales y lectinas. Objetivo. Evaluar diferencias de expresión del antígeno Tn en cortes histológicos de epitelios no neoplásicos y tumores epiteliales mediante isolectina B4 de Vicia villosa.Material y métodos. Se evaluaron semicuantitativamente localización, intensidad y porcentaje de expresión del antígeno en carcinomas in-situ e infiltrantes y epitelios no neoplásicos de cérvix, seno y urotelio, mediante isolectina B4.Resultados La expresión de Tn en cérvix predominó en membrana de células no neoplásicas y citoplasma de células tumorales; su intensidad fue mayor en carcinomas in-situ e infiltrantes comparado con epitelio no neoplásico aunque en este el porcentaje de expresión fue mayor. En seno, la expresión de Tn fue predominantemente citoplasmática con intensidad similar, el porcentaje de expresión fué mayor en carcinomas ductales in-situ e infiltrantes. En urotelio no neoplásico y tumoral la expresión de Tn predominó en citoplasma; la intensidad y el porcentaje de expresión fueron mayores en neoplasias no invasivas de bajo y alto grado, mientras que en urotelio no neoplásico fue baja y no hubo tendencia definida en tumores infiltrantes.Conclusiones. La detección del antígeno Tn mediante la lectina VVB4 mostró una mayor extensión de marcación en carcinomas ductales de seno en relación con el epitelio no neoplásico, pero no mostró una tendencia definida entre el tejido normal, ni diferentes etapas del desarrollo de los tumores de cérvix y urotelio. Estos hallazgos pueden atribuirse a la heterogeneidad de los procesos carcinogénicos o a que la especificidad de la lectina VVB4 no está restringida a este antígeno.

Published
2010

4. Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country

Author

Cifuentes, Claudia, Lombana, Milton, Vargas, Henry, Laguado, Paola, Ruiz-Patiño, Alejandro, Rojas, Leonardo, Navarro, Uriel, Vargas, Carlos, Ricaurte, Luisa, Arrieta, Oscar, Zatarain-Barron, Lucia, Zapata, Leandro, González, Guido, Ortiz, Carlos, Bernal, Laura, Restrepo, Juan G., Viola, Lucia, Grosso, Fabio, Zapata, Ricardo, Mantilla, William, Carranza, Hernán, Bustillo, Iván, Llinas, Néstor, Duarte, Ricardo, Rodríguez, July, Archila, Pilar, Ávila, Jenny, Bermúdez, Maritza, Gámez, Tatiana, Sotelo, Carolina, Otero, Jorge, Forero, Elkin, Lema, Mauricio, Limpias, Catalina, Ordóñez-Reyes, Camila, Mejía, Sergio, Rolfo, Christian, Rosell, Rafael, and Cardona, Andrés F.

Abstract

Purpose Identifying actionable oncogenic mutations have changed the therapeutic landscape in different types of tumors. This study investigated the utility of comprehensive genomic profiling (CGP), a hybrid capture-based next-generation sequencing (NGS) assay, in clinical practice in a developing country.Methods In this retrospective cohort study, CGP was performed on clinical samples from patients with different solid tumors recruited between December 2016 and November 2020, using hybrid capture-based genomic profiling, at the individual treating physicians’ request in the clinical care for therapy decisions. Kaplan–Meier survival curves were estimated to characterize the time-to-event variables.Results Patients median age was 61 years (range: 14–87 years), and 64.7% were female. The most common histological diagnosis was lung primary tumors, with 90 patients corresponding to 52.9% of the samples (95% CI 45.4-60.4%). Actionable mutations with FDA-approved medications for specific alterations correspondent to tumoral histology were identified in 58 cases (46.4%), whereas other alterations were detected in 47 different samples (37.6%). The median overall survival was 15.5 months (95% CI 11.7 months-NR). Patients who were subjected to genomic evaluation at diagnosis reached a median overall survival of 18.3 months (95% CI 14.9 months-NR) compared to 14.1 months (95% CI 11.1 months-NR) in patients who obtained genomic evaluation after tumor progression and during standard treatment (P= .7).Conclusion CGP of different types of tumors identifies clinically relevant genomic alterations that have benefited from targeted therapy and improve cancer care in a developing country to guide personalized treatment to beneficial outcomes of cancer patients.

Published
2023
Full Text
View/download PDF

5. Application of Comprehensive Genomic Profiling-Based Next-Generation Sequencing Assay to Improve Cancer Care in a Developing Country.

Author

Cifuentes C, Lombana M, Vargas H, Laguado P, Ruiz-Patiño A, Rojas L, Navarro U, Vargas C, Ricaurte L, Arrieta O, Zatarain-Barron L, Zapata L, González G, Ortiz C, Bernal L, Restrepo JG, Viola L, Grosso F, Zapata R, Mantilla W, Carranza H, Bustillo I, Llinas N, Duarte R, Rodríguez J, Archila P, Ávila J, Bermúdez M, Gámez T, Sotelo C, Otero J, Forero E, Lema M, Limpias C, Ordóñez-Reyes C, Mejía S, Rolfo C, Rosell R, and Cardona AF

Subjects
Humans, Female, Middle Aged, Male, Retrospective Studies, Mutation, Genomics, High-Throughput Nucleotide Sequencing, Developing Countries, Lung Neoplasms pathology
Abstract

Purpose: Identifying actionable oncogenic mutations have changed the therapeutic landscape in different types of tumors. This study investigated the utility of comprehensive genomic profiling (CGP), a hybrid capture-based next-generation sequencing (NGS) assay, in clinical practice in a developing country., Methods: In this retrospective cohort study, CGP was performed on clinical samples from patients with different solid tumors recruited between December 2016 and November 2020, using hybrid capture-based genomic profiling, at the individual treating physicians' request in the clinical care for therapy decisions. Kaplan-Meier survival curves were estimated to characterize the time-to-event variables., Results: Patients median age was 61 years (range: 14-87 years), and 64.7% were female. The most common histological diagnosis was lung primary tumors, with 90 patients corresponding to 52.9% of the samples (95% CI 45.4-60.4%). Actionable mutations with FDA-approved medications for specific alterations correspondent to tumoral histology were identified in 58 cases (46.4%), whereas other alterations were detected in 47 different samples (37.6%). The median overall survival was 15.5 months (95% CI 11.7 months-NR). Patients who were subjected to genomic evaluation at diagnosis reached a median overall survival of 18.3 months (95% CI 14.9 months-NR) compared to 14.1 months (95% CI 11.1 months-NR) in patients who obtained genomic evaluation after tumor progression and during standard treatment ( P = .7)., Conclusion: CGP of different types of tumors identifies clinically relevant genomic alterations that have benefited from targeted therapy and improve cancer care in a developing country to guide personalized treatment to beneficial outcomes of cancer patients.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results